Abiraterone Acetate - Zytiga

On April 28, 2011, the US Food and Drug Administration (FDA) approved Zytiga (abiraterone acetate), for use in combination with prednisone for the second-line treatment of castration-resistant prost...

Varicella

Varicella zoster virus (VZV) is one of eight herpes viruses known to infect humans (and other vertebrates). Varicella-zoster virus is known by many names, including: chickenpox virus, varicella viru...

What is new in prostate cancer research and development?

Key research areas in relation to Prostate Cancer are discussed below.  Brief descriptions are supported by hyperlinks to the most relevant research papers and current affairs news reports and...

Zytiga pre-chemo data published

Having secured the US FDA's blessing for an expanded label for Zytiga (abiraterone), Janssen has now published the data from the COU-AA-302 study, which formed the basis of that approval. Earlier this...

Johnson & Johnson files for new Zytiga approval

Johnson & Johnson said Friday it has asked U.S. and European Union regulators to grant broader marketing approval for its cancer pill Zytiga.Zytiga was approved in 2011 for the treatment of advanced...

Johnson & Johnson files for new Zytiga approval

Johnson & Johnson said Friday it has asked U.S. and European Union regulators to grant broader marketing approval for its cancer pill Zytiga.Zytiga was approved in 2011 for the treatment of advanced...

Extended Use Of Zytiga Approved By FDA For Late-Stage Prostate Cancer

Today the U.S. Food and Drug Administration (FDA) lengthened the approved use of Zytiga (abiraterone acetate) as treatment for men with late-stage, castration-resistant prostate cancer (metastatic) be...

Zytiga zooms to front

Many clinicians say the case has been made to use J&J's Zytiga in chemo-naïve mCRPC, and that the drug will complement rather than replace Provenge once more data can guide dosing of the combination.

Zytiga meets Phase III endpoint in chemo-naive CRPC

Johnson & Johnson (NYSE:JNJ) said Zytiga abiraterone met the co-primary endpoint of radiographic progression-free survival vs. prednisone alone in a Phase III trial to treat chemotherapy-naive castrat...

Johnson & Johnson's Pioneering Zytiga And Its Competitors

By Peter Geschek: Zytiga In its first full year on the market, in 2012, Johnson & Johnson's prostate cancer medicine Zytiga generated $961 million in revenues which make it a "near blockbuster"....

J&J files for second Zytiga marketing approval

Johnson & Johnson said Wednesday that regulators will conduct a faster review of its prostate cancer pill Zytiga as the company seeks a new marketing approval.The Food and Drug Administration will co...

Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.

Development and Pilot Testing of a Fertility Decision Aid for Young Women Diagnosed with Early Breast Cancer.

OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.

Cancer clinical trials in Australia.

Improving the uptake of screening for diabetic retinopathy.